Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2012 December;37(4) > Minerva Endocrinologica 2012 December;37(4):367-77





A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118




Minerva Endocrinologica 2012 December;37(4):367-77

language: English

Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors?

Cuccurullo V. 1, Faggiano A. 2, Scialpi M. 3, Cascini G. L. 4, Piunno A. 2, Catalano O. 5, Colao A. 2, Mansi L. 1

1 Department of Nuclear Medicine, Seconda Università degli Studi, Naples, Italy;
2 Department of Endocrinology and Molecular Clinical Oncology, Federico II University, Naples, Italy;
3 Department of Surgical, Radiological and Odontostomatological Sciences, Perugia University, S. Maria della Misericordia Hospital, S. Andrea delle Fratte, Perugia, Italy;
4 Department of Nuclear Medicine, “Magna Graecia” University, Catanzaro, Italy;
5 Radiodiagnostic Operative Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, Naples, Italy


The neuroendocrine tumors (NET) of the gastro-entero-pancreatic area (GEP) represent a heterogeneous group of malignancies from the histologic, clinico-laboratoristic (functioning and non-functioning variants), and therapeutic point of view. It is an issue becoming more frequent for the diagnostic imager, being radiologist as well as nuclear physician. Imaging (together with biopsy) plays a key role in the diagnostic assessment and staging (including grading and prognostic definition), in evaluating response to treatment, and in follow-up of GEP-NET. Multislice computed tomography (MSCT), octreoscan and PET-CT are the most widely diffuse and accurate imaging modalities employed in this setting. Other methods, such as Magnetic Resonance and Endoscopic Ultrasound, may also play a significant role.

top of page

Publication History

Cite this article as

Corresponding author e-mail